Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies. Read More

Viracta Therapeutics to Present at the Solebury Trout Fall Private Company Showcase 2020

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the Solebury Trout Fall Private Company Showcase on Thursday, October 15, 2020 at 1:00 pm ET. Read More

Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD, FACP as Chairman of the Board of Directors

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced the appointment of Roger J. Pomerantz, MD, FACP, as Chairman of its Board of Directors. Read More

Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 3:00 pm ET. Read More

Events

November 30, 2020

Definitive Merger Agreement Conference Call Attend Call

October 15, 2020

Viracta Therapeutics to Present at the Solebury Trout Fall Private Company Showcase 2020 Read More

September 15, 2020

Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Read More

June 5, 2020

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma Read More | Watch Replay

Recent News

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies. Read More

Viracta Therapeutics to Present at the Solebury Trout Fall Private Company Showcase 2020

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the Solebury Trout Fall Private Company Showcase on Thursday, October 15, 2020 at 1:00 pm ET. Read More

Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD, FACP as Chairman of the Board of Directors

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced the appointment of Roger J. Pomerantz, MD, FACP, as Chairman of its Board of Directors. Read More

Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 3:00 pm ET. Read More

Events

November 30, 2020

Definitive Merger Agreement Conference Call Attend Call

October 15, 2020

Viracta Therapeutics to Present at the Solebury Trout Fall Private Company Showcase 2020 Read More

September 15, 2020

Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Read More

June 5, 2020

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma Read More | Watch Replay